Nektar Therapeutics (NKTR)
1.34
+0.11
(+8.94%)
USD |
NASDAQ |
Nov 04, 16:00
1.335
0.00 (0.00%)
After-Hours: 20:00
Nektar Therapeutics Gross Profit Margin (Quarterly): 58.53% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 58.53% |
| March 31, 2024 | 60.56% |
| December 31, 2023 | 69.51% |
| September 30, 2023 | 48.51% |
| June 30, 2023 | 65.88% |
| March 31, 2023 | 67.31% |
| December 31, 2022 | 71.70% |
| September 30, 2022 | 78.95% |
| June 30, 2022 | 76.30% |
| March 31, 2022 | 78.59% |
| December 31, 2021 | 75.36% |
| September 30, 2021 | 78.69% |
| June 30, 2021 | 72.94% |
| March 31, 2021 | 75.66% |
| December 31, 2020 | 81.57% |
| September 30, 2020 | 81.45% |
| June 30, 2020 | 88.18% |
| March 31, 2020 | 92.46% |
| December 31, 2019 | 82.31% |
| September 30, 2019 | 83.14% |
| June 30, 2019 | 78.48% |
| March 31, 2019 | 80.72% |
| December 31, 2018 | 81.27% |
| September 30, 2018 | 82.77% |
| June 30, 2018 | 99.49% |
| Date | Value |
|---|---|
| March 31, 2018 | 82.52% |
| December 31, 2017 | 89.78% |
| September 30, 2017 | 96.29% |
| June 30, 2017 | 74.01% |
| March 31, 2017 | 75.21% |
| December 31, 2016 | 82.37% |
| September 30, 2016 | 80.64% |
| June 30, 2016 | 76.48% |
| March 31, 2016 | 84.94% |
| December 31, 2015 | 78.76% |
| September 30, 2015 | 88.72% |
| June 30, 2015 | 53.51% |
| March 31, 2015 | 92.24% |
| December 31, 2014 | 67.79% |
| September 30, 2014 | 93.06% |
| June 30, 2014 | 82.09% |
| March 31, 2014 | 60.01% |
| December 31, 2013 | 71.23% |
| September 30, 2013 | 78.86% |
| June 30, 2013 | 85.20% |
| March 31, 2013 | 49.31% |
| December 31, 2012 | 65.53% |
| September 30, 2012 | 60.74% |
| June 30, 2012 | 69.59% |
| March 31, 2012 | 51.49% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
48.51%
Minimum
Sep 2023
92.46%
Maximum
Mar 2020
73.92%
Average
75.66%
Median
Mar 2021
Gross Profit Margin (Quarterly) Benchmarks
| Eli Lilly and Co | 81.02% |
| Esperion Therapeutics Inc | 78.86% |
| NovaBay Pharmaceuticals Inc | 66.33% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -127.6% |
| Return on Assets | -42.69% |
| Return on Invested Capital | -127.6% |
| Profit Margin (Quarterly) | -222.9% |
| Operating Margin (Quarterly) | -155.3% |
| Return on Net Operating Assets | -271.7% |